Superluminal Medicines Overview
- Year Founded
-
2022
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$65.5M
- Investors
-
13
Superluminal Medicines General Information
Description
Developer of a generative biology medicine technology designed to accelerate new possibilities in drug discovery and development. The company creates candidate-ready compounds using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure, enabling the pharmaceutical industry to accelerate drug discovery and increase the probability of success in small-molecule drug development.
Contact Information
Website
www.superluminalrx.comCorporate Office
- 15 Necco Street
- Lilly Gateway Labs, 4th Floor
- Boston, MA 02210
- United States
Corporate Office
- 15 Necco Street
- Lilly Gateway Labs, 4th Floor
- Boston, MA 02210
- United States
Superluminal Medicines Timeline
Superluminal Medicines Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 03-Sep-2026 | $65.5M | Completed | Pre-Clinical Trials | ||
| 2. Early Stage VC (Series A) | 24-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 28-Aug-2023 | $32.7M | $32.7M | Completed | Pre-Clinical Trials |
Superluminal Medicines Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | ||||||||
| Series B1 | ||||||||
| Series A | ||||||||
| Seed-2 | 31,365,451 | $0.000100 | $1.01 | $1.01 | 1x | $1.01 | 16.77% | |
| Seed-1 | 1,060,445 | $0.000100 | $0.94 | $0.94 | 1x | $0.94 | 0.57% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Superluminal Medicines Comparisons
Industry
Financing
Details
Superluminal Medicines Competitors (3)
One of Superluminal Medicines’s 3 competitors is Generate Biomedicines, a Formerly VC-backed company based in Somerville, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Generate Biomedicines | Formerly VC-backed | Somerville, MA | ||||
| Ordaos | Venture Capital-Backed | New York, NY | ||||
| InSilico Medicine Cayman | Formerly VC-backed | Hong Kong, Hong Kong |
Superluminal Medicines Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Superluminal Medicines Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Superluminal Medicines Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BVF Partners | Hedge Fund | Minority | ||
| Deep Track Capital | Venture Capital | Minority | ||
| Eli Lilly and Company Foundation | Limited Partner | Minority | ||
| NVIDIA | Corporation | Minority | ||
| Perceptive Advisors | Venture Capital | Minority |
Superluminal Medicines FAQs
-
When was Superluminal Medicines founded?
Superluminal Medicines was founded in 2022.
-
Where is Superluminal Medicines headquartered?
Superluminal Medicines is headquartered in Boston, MA.
-
What is the size of Superluminal Medicines?
Superluminal Medicines has 29 total employees.
-
What industry is Superluminal Medicines in?
Superluminal Medicines’s primary industry is Drug Discovery.
-
Is Superluminal Medicines a private or public company?
Superluminal Medicines is a Private company.
-
What is the current valuation of Superluminal Medicines?
The current valuation of Superluminal Medicines is .
-
What is Superluminal Medicines’s current revenue?
The current revenue for Superluminal Medicines is .
-
How much funding has Superluminal Medicines raised over time?
Superluminal Medicines has raised $218M.
-
Who are Superluminal Medicines’s investors?
BVF Partners, Deep Track Capital, Eli Lilly and Company Foundation, NVIDIA, and Perceptive Advisors are 5 of 13 investors who have invested in Superluminal Medicines.
-
Who are Superluminal Medicines’s competitors?
Generate Biomedicines, Ordaos, and InSilico Medicine Cayman are competitors of Superluminal Medicines.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
